European Organization for Research and Treatment of Cancer
53 articles about European Organization for Research and Treatment of Cancer
-
Merck’s KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression
1/10/2022
Merck, the EORTC and the ETOP announced that the Phase 3 KEYNOTE-091 trial, also known as EORTC-1416-LCG/ETOP-8-15 – PEARLS, investigating KEYTRUDA, Merck’s anti-PD-1 therapy, met one of its dual primary endpoints of disease-free survival for the adjuvant treatment of patients with stage IB-IIIA non-small cell lung cancer following surgical resection regardless of PD-L1 expression.
-
The U.S. Food and Drug Administration (FDA) accepted Merck’s new supplemental Biologics License Application (sBLA) for Keytruda.
-
CTI BioPharma Presents Nonclinical Pharmacology Study Demonstrating Pacritinib Has Distinct Profile Amongst JAK Inhibitors At European Organization for Research and Treatment of Cancer-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium
12/2/2016
-
Arvinas Presents Data On Its BET PROTAC Degraders At 2016 European Organization for Research and Treatment of Cancer-NCI-AACR Symposium
11/29/2016
-
14M Genomics Ltd. And European Organization for Research and Treatment of Cancer Announce First Results From Their Collaboration On Tumor Profiling
11/16/2015
-
Inovio Pharmaceuticals And European Organization for Research and Treatment of Cancer To Collaborate On Large Phase II Cervical Cancer Trial
7/23/2015
-
OncoMed Pharmaceuticals, Inc. Presents New Clinical And Biomarker Data From Its Tarextumab And Demcizumab Clinical Trials At The European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research
11/24/2014
-
Merrimack Pharmaceuticals Inc. Presents On Multiple Programs At The 26th European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium On Molecular Targets And Cancer Therapeutics
11/21/2014
-
OncoMed Pharmaceuticals, Inc. Presents Biomarker-Focused Clinical Data From Phase 1a Trial Of Anti-Notch1 (OMP-52M51) In Oral Plenary Session At The 26th OncoMed Pharmaceuticals, Inc.-European Organization for Research and Treatment of Cancer-National Can
11/19/2014
-
Champions Oncology, Inc. Release: Presentations At 26th Champions Oncology, Inc.-European Organization for Research and Treatment of Cancer-National Cancer Institute Symposium Highlight Champions Oncology TumorGrafts' Ability To Evaluate Immune-Modulating
11/19/2014
-
3-V Biosciences Announces Presentation Of First Human Clinical Data For Lead Oral FASN Inhibitor Candidate At European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research 2014
11/19/2014
-
Debiopharm Group Presents Advances Of Two Key Oncology Clinical Programs At The 26th European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium In Barcelona
11/18/2014
-
Merrimack Pharmaceuticals Inc. To Present Advances On Targeted Cancer Molecules At The 2014 American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer International Conference
11/14/2014
-
OncoMed Pharmaceuticals, Inc. To Present Clinical And Preclinical Data At The 26th European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium On Molecular Targets And Cancer Ther
10/30/2014
-
Loxo Oncology To Present Pre-Clinical Data On LOXO-101 At Upcoming European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium
10/30/2014
-
OncoMed Pharmaceuticals, Inc. to Present Data From Clinical Trials of Four Novel Anti-Cancer Stem Cell (anti-CSC) Therapeutics in Five Posters at the American Association for Cancer Research-National Cancer Institute-EORTC International Conference on Mole
10/14/2013
-
Tesaro, Inc., Breast International Group (BIG), and the European Organization for Research and Treatment of Cancer Announce Collaboration for Niraparib Clinical Development in Breast Cancer
6/3/2013
-
Verastem, Inc. Reports Data on Focal Adhesion Kinase Program at the 2012 European Organization for Research and Treatment of Cancer Symposium on Molecular Targets and Cancer Therapeutics
11/9/2012
-
OncoMed Pharmaceuticals, Inc. Announces Presentations of Anti-Notch2/3 and Demcizumab Clinical Data at European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Meeting
11/9/2012
-
MethylGene Presents MGCD265 Data at the 24th European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics
11/8/2012